PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-15.16%
Negative net income growth while CRVO stands at 8.50%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
8.11%
D&A growth well above CRVO's 3.07%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
14.88%
Lower deferred tax growth vs. CRVO's 100.00%, implying fewer future tax liabilities. David Dodd would confirm there’s no short-term tax shock instead.
33.33%
SBC growth while CRVO is negative at -45.68%. John Neff would see competitor possibly controlling share issuance more tightly.
-359.86%
Both reduce yoy usage, with CRVO at -65.71%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-185.03%
Negative yoy usage while CRVO is 95.20%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-14.88%
Negative yoy while CRVO is 0.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-25.31%
Negative yoy CFO while CRVO is 3.29%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-2962.50%
Negative yoy CapEx while CRVO is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2962.50%
We reduce yoy invests while CRVO stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
56.30%
Debt repayment growth of 56.30% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
23135.79%
Issuance growth of 23135.79% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
100.00%
Buyback growth of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.